ARTICLE | Top Story
REGN reports Phase II Axokine obesity data
November 28, 2000 8:00 AM UTC
In a U.S. Phase II study of 170 severely or morbidly obese patients, Regeneron (REGN) said that its Axokine second generation ciliary neurotrophic factor ( CNTF) gave significant weight loss compared ...